Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 23Recurrence 3Neoplasms, Plasma Cell 2Smoldering Multiple Myeloma 1Neoplasms 1Neoplasm, Residual 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Dexamethasone 13Lenalidomide 11daratumumab 5carfilzomib 5Bortezomib 5Calcium Dobesilate 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Cyclophosphamide 3ixazomib 2isatuximab 2fludarabine phosphate 2fludarabine 2belantamab mafodotin 2Etoposide 2venetoclax 1thymoglobulin 1selinexor 1pomalidomide 1poly ICLC 1citarinostat 1Transplantation 1Thalidomide 1Sirolimus 1Rituximab 1Positron Emission Tomography Computed Tomography 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Plasma Cell × isatuximab × Clear all
NCT04751877 2026-02-10

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Poitiers University Hospital

Phase 3 Active not recruiting
270 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04891809 2025-04-10

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Arbeitsgemeinschaft medikamentoese Tumortherapie

Phase 2 Active not recruiting
198 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡